Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 768 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... February 3, 2023 Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 “Scars are Tattoos with Better Stories” July 21, 2021 Discover and translate – a mantra to work by October 17, 2022 Load more HOT NEWS Increase in Node-Positive and Stage III Breast Cancer After Two Months... Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι... Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer... Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast...
